Research on the function and targeted therapy of BCL9 in malignant tumors

doi:10.3760/cma.j.cn371439-20200224-00048

Abstract

Abstract:

Canonical Wnt/β-catenin signaling pathway is of great significance to the occurrence and progression of tumors which make it an exciting target in cancer therapy. The pathway is also required in regeneration of normal tissues, so the specificity of inhibitors targeting this pathway may be affected. The coactivator of β-catenin, B cell lymphoma 9 (BCL9), is highly expressed merely in tumor cells. Accordingly, inhibitors targeting the interaction between β-catenin and BCL9 may demonstrate robust specificity and minimal toxicity. BCL9 increases tumor growth, invasion and metastasis by promoting epithelial-mesenchymal transition, up-regulating vascular endothelial growth factor and CD44 expression and regulating cancer stem cell traits. BCL9 promises to be a new target for cancer therapy.

Key words: Wnt signaling pathway, Neoplasms, Molecular targeted therapy

Zhai Jingtong, Ma Fei. Research on the function and targeted therapy of BCL9 in malignant tumors[J]. Journal of International Oncology, 2020, 47(7): 419-422.

References 26

[1]	Schaefer KN, Peifer M. Wnt/beta-catenin signaling regulation and a role for biomolecular condensates[J]. Dev Cell, 2019,48(4):429-444. DOI: 10.1016/j.devcel.2019.01.025. doi: 10.1016/j.devcel.2019.01.025 pmid: 30782412
[2]	Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors[J]. Cancer Treat Rev, 2018,62:50-60. DOI: 10.1016/j.ctrv.2017.11.002. pmid: 29169144
[3]	Feng M, Jin JQ, Xia L, et al. Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T_reg cells[J]. Sci Adv, 2019, 5(5): eaau5240. DOI: 10.1126/sciadv.aau5240. doi: 10.1126/sciadv.aau5240 pmid: 31086813
[4]	Zhang J, Tian XJ, Xing J. Signal transduction pathways of EMT induced by TGF-β, SHH, and WNT and their crosstalks[J]. J Clin Med, 2016,5(4):41. DOI: 10.3390/jcm5040041.
[5]	Moor AE, Anderle P, Cantù C, et al. BCL9/9L-β-catenin signaling is associated with poor outcome in colorectal cancer[J]. EBioMedicine, 2015,2(12):1932-1943. DOI: 10.1016/j.ebiom.2015.10.030. doi: 10.1016/j.ebiom.2015.10.030 pmid: 26844272
[6]	Luo M, Hou L, Li J, et al. VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin[J]. Cancer Lett, 2016,373(1):1-11. DOI: 10.1016/j.canlet.2016.01.010. doi: 10.1016/j.canlet.2016.01.010 pmid: 26805761
[7]	Linke F, Harenberg M, Nietert MM, et al. Microenvironmental interactions between endothelial and lymphoma cells: a role for the cano-nical WNT pathway in Hodgkin lymphoma[J]. Leukemia, 2017,31(2):361-372. DOI: 10.1038/leu.2016.232. doi: 10.1038/leu.2016.232 pmid: 27535218
[8]	Pascual G, Avgustinova A, Mejetta S, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36[J]. Nature, 2017,541(7635):41-45. DOI: 10.1038/nature20791. pmid: 27974793
[9]	Schmitt M, Metzger M, Gradl D, et al. CD44 functions in Wnt signaling by regulating LRP6 localization and activation[J]. Cell Death Differ, 2015,22(4):677-689. DOI: 10.1038/cdd.2014.156. doi: 10.1038/cdd.2014.156 pmid: 25301071
[10]	Zhan T, Ambrosi G, Wandmacher AM, et al. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer[J]. Nat Commun, 2019,10(1):2197. DOI: 10.1038/s41467-019-09898-0. doi: 10.1038/s41467-019-09898-0 pmid: 31097693
[11]	Gay DM, Ridgway RA, Müller M, et al. Loss of BCL9/9l sup-presses Wnt driven tumourigenesis in models that recapitulate human cancer[J]. Nat Commun, 2019,10(1):723. DOI: 10.1038/s41467-019-08586-3. doi: 10.1038/s41467-019-08586-3 pmid: 30760720
[12]	Elsarraj HS, Hong Y, Valdez KE, et al. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion[J]. Breast Cancer Res, 2015,17:128. DOI: 10.1186/s13058-015-0630-z. doi: 10.1186/s13058-015-0630-z pmid: 26384318
[13]	Madani SH, Payandeh M, Sadeghi M, et al. The correlation between Ki-67 with other prognostic factors in breast cancer: a study in Iranian patients[J]. Indian J Med Paediatr Oncol, 2016,37(2):95-99. DOI: 10.4103/0971-5851.180136. doi: 10.4103/0971-5851.180136 pmid: 27168707
[14]	Jiang M, Kang Y, Sewastianik T, et al. BCL9 provides multi-cellular communication properties in colorectal cancer by interacting with paraspeckle proteins[J]. Nat Commun, 2020,11(1):19. DOI: 10.1038/s41467-019-13842-7. doi: 10.1038/s41467-019-13842-7 pmid: 31911584
[15]	Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma[J]. Cell, 2017, 169(7): 1327-1341. e1323. DOI: 10.1016/j.cell.2017.05.046.
[16]	Huge N, Sandbothe M, Schröder AK, et al. Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma[J]. Hepatol Int, 2020,14(3):373-384. DOI: 10.1007/s12072-019-09977-w. doi: 10.1007/s12072-019-09977-w pmid: 31440992
[17]	Xu W, Zhou W, Cheng M, et al. Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocel-lular carcinoma[J]. Sci Rep, 2017,7:40446. DOI: 10.1038/srep40446. doi: 10.1038/srep40446 pmid: 28074862
[18]	Cai J, Fang L, Huang Y, et al. Simultaneous overactivation of Wnt/β-catenin and TGFβ signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC[J]. Nat Commun, 2017,8:15870. DOI: 10.1038/ncomms15870. doi: 10.1038/ncomms15870 pmid: 28627514
[19]	Zhang Y, Zhang Q, Chen H, et al. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway[J]. Life Sci, 2018,208:284-294. DOI: 10.1016/j.lfs.2018.07.023. doi: 10.1016/j.lfs.2018.07.023 pmid: 30009824
[20]	Mita MM, Becerra C, Richards DA, et al. Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1^st- to 3^rd-line metastatic HER2-negative breast cancer (BC) [J]. J Clin Oncol, 2016,34(15_suppl):2516. DOI: 10.1200/JCO.2016.34.15_suppl.2516. doi: 10.1200/JCO.2015.66.0787
[21]	Le PN, McDermott JD, Jimeno A. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28[J]. Pharmacol Ther, 2015,146:1-11. DOI: 10.1016/j.pharmthera.2014.08.005. doi: 10.1016/j.pharmthera.2014.08.005 pmid: 25172549
[22]	Moore KN, Gunderson CC, Sabbatini P, et al. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer[J]. Gynecol Oncol, 2019,154(2):294-301. DOI: 10.1016/j.ygyno.2019.04.001. doi: 10.1016/j.ygyno.2019.04.001 pmid: 31174889
[23]	Mariotti L, Pollock K, Guettler S. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding[J]. Br J Pharmacol, 2017,174(24):4611-4636. DOI: 10.1111/bph.14038. doi: 10.1111/bph.14038 pmid: 28910490
[24]	Arqués O, Chicote I, Puig I, et al. Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer[J]. Clin Cancer Res, 2016,22(3):644-656. DOI: 10.1158/1078-0432.CCR-14-3081. doi: 10.1158/1078-0432.CCR-14-3081 pmid: 26224873
[25]	Fang L, Zhu Q, Neuenschwander M, et al. A small-molecule ant-agonist of the β-Catenin/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis[J]. Cancer Res, 2016,76(4):891-901. DOI: 10.1158/0008-5472.CAN-15-1519. doi: 10.1158/0008-5472.CAN-15-1519 pmid: 26645562
[26]	Hwang SY, Deng X, Byun S, et al. Direct targeting of β-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/β-catenin signaling[J]. Cell Rep, 2016,16(1):28-36. DOI: 10.1016/j.celrep.2016.05.071. doi: 10.1016/j.celrep.2016.05.071 pmid: 27320923